Received: 26 February 2020
Accepted: 17 June 2020
First Online: 8 July 2020
Ethics approval and consent to participate
: The patient whose data is included in this study participated in a clinical trial (EudraCT-nr 2011-000240-16) with dosimetry-based [ <sup>177</sup>Lu]Lu-DOTA-TATE therapy for the treatment of neuroendocrine tumours. The trial has been approved by the local ethics committee (Regionala Etikprövningsnämden Lund, ref. no. 2011/287) and by the national regulatory authorities.
: The patient gave written informed consent to participation and publication of data related to the trial and gave verbal consent to contribute with the measurements published herein.
: AS has been a consultant, lecturer, and advisory board member for Novartis, Ipsen, and Spago Nanomedical. KSG has been a consultant for Fusion Pharmaceuticals Inc. DR and EL declare that they have nothing to disclose.